세계 경피 약물전달 시스템 시장 규모는 2024년 71억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 115억 달러에 달할 것으로 예상하며, 2025-2033년 5.22%의 연평균 성장률(CAGR)을 기록할 것으로 전망하고 있습니다. 당뇨병, 심혈관질환, 신경질환 등 만성질환의 유병률 증가, 노인 인구 증가, 규제 당국의 승인 증가 등 다양한 요인이 시장을 주도하고 있습니다.
만성질환 증가
사람들은 앉아서 생활하는 생활습관과 식습관 장애로 인해 당뇨병, 심장병, 류마티스 관절염, 고혈압, 신경질환 등 만성질환에 걸리기 쉽습니다. 이러한 질환을 앓고 있는 환자들은 장기간에 걸쳐 약을 복용해야 하기 때문에 신뢰할 수 있고 편리한 약물전달 옵션을 찾아야 합니다. 경피흡수형 패치는 자주 사용할 필요가 없고 약물을 안정적으로 지속시킬 수 있어 가장 효과적입니다. 환자의 순응도를 높일 수 있는 비침습적이고 사용하기 쉬운 대안에 대한 수요가 증가하면서 경피 약물전달 시스템 시장의 성장을 견인하고 있습니다. 경피흡수형 시스템을 사용하는 환자는 주기적으로 패치를 붙이는 것만으로도 복용 누출 가능성을 낮출 수 있습니다. 만성질환을 앓고 있는 사람들은 보다 편리한 솔루션을 원하고 있습니다. 세계신경학연맹(World Federation of Neurology)의 획기적인 새로운 세계 질병부담(Global Burden of Disease : GBD) 조사에 따르면, 2050년까지 뇌질환을 앓고 있는 사람의 수가 두 배로 증가할 것으로 예상됩니다.
노인 인구 증가
고령화 사회에서 경피투약 시스템에 대한 니즈가 증가함에 따라 시장이 확대되고 있습니다. 나이가 들면 신경질환, 당뇨병, 류마티스 관절염, 심혈관질환 등 여러 만성질환에 걸릴 확률이 높아집니다. 노인의 경우, 이러한 약물을 장기간 꾸준히 복용하는 것이 어려울 수 있습니다. 노인들이 약을 삼키지 못하는 것도 전형적인 문제입니다. 경피 약물전달 시스템은 경구용 약물을 복용할 필요를 피하고 비침습적인 약물 서방출 방법을 제공하는 능력으로 편리한 대안을 제공합니다. 또한, 노인들 사이에서 하루에 여러 번 복용하는 부담을 덜어주는 더 간단한 솔루션에 대한 요구가 증가하고 있으며, 경피 약물전달 시스템 시장 전망은 양호합니다. 세계보건기구(WHO)는 2050년까지 80세 이상 노인 인구가 4억 2,600만 명에 달할 것으로 예측하고 있습니다.
높아지는 규제 당국의 승인
중국 국가약품감독관리국(NMPA)은 2023년 10월 31일, 루예제약그룹의 신약 리바스티그민 주 2회 경피흡수형 패치를 경증에서 중등도 알츠하이머병(AD)의 증상 치료제로 승인했습니다. 규제 당국은 보다 광범위한 경피흡수형 제제를 승인하고 있습니다. 여기에는 호르몬 보충, 통증 완화, 예방접종 등 다양한 의약품 용도의 패치가 포함됩니다. 경피시스템이 더 널리 보급되고 종류가 다양해지면서 더 많은 환자와 의료 전문가를 끌어들이고 있습니다.
The global transdermal drug delivery systems market size reached USD 7.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.5 Billion by 2033, exhibiting a growth rate (CAGR) of 5.22% during 2025-2033. There are various factors that are driving the market, which include the growing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and neurological disorders, rising geriatric population, and increasing regulatory approvals.
Growing Prevalence of Chronic Diseases
People are becoming prone to chronic illnesses like diabetes, heart disease, rheumatoid arthritis, hypertension, and neurological disorders because of sedentary lifestyles and poor eating habits. Patients with these disorders need to take medication continuously for a longer time, which prompts them to look for reliable and convenient drug delivery options. For this, transdermal patches work best as they provide a steady flow of medication throughout time without requiring frequent use. The rising demand for non-invasive and easy-to-use alternative that can enhance patient compliance is impelling the transdermal drug delivery systems market growth. Patients using transdermal systems just need to apply a patch on a regular basis, which helps to lower the possibility of missing doses. People with chronic diseases are looking for solutions that offer enhanced convenience. According to the World Federation of Neurology, a groundbreaking new Global Burden of Disease (GBD) study shows that the number of people living with brain disease is expected to double by 2050.
Increasing Geriatric Population
The market is expanding as a result of the growing need for transdermal medication delivery systems among the aging population. People frequently acquire several chronic illnesses as they get older, including neurological disorders, diabetes, rheumatoid arthritis, and cardiovascular ailments. It might be difficult for elderly individuals to take these medications consistently over an extended period. The inability of the elderly to swallow medications is another typical problem. Transdermal drug delivery systems offer a convenient alternative because of their ability to bypass the need to take oral medications and provide a non-invasive method for sustained drug release. Furthermore, the growing need for simpler solutions among older individuals that lowers the burden of multiple daily doses is offering a favorable transdermal drug delivery systems market outlook. The World Health Organization (WHO) claims that the number of people aged 80 years or older is expected to reach 426 million by 2050.
Rising Regulatory Approvals
The National Medical Products Administration (NMPA) of China approved Luye Pharma Group's novel medicine, Rivastigmine Twice Weekly Transdermal Patch, on October 31, 2023, for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). Regulatory agencies are increasingly approving a broader range of transdermal products. This covers patches for a range of medicinal applications such as hormone replacement, pain relief, and even immunizations. Transdermal systems are becoming more widely available and varied, which is drawing in more patients and healthcare professionals.
Iontophoresis accounts for the majority of the market share
Iontophoresis uses a small electric current to improve the diffusion of drugs via the skin. It is favored because of its ability to deliver precise dosages of medication while lowering side effects. It is especially useful for pain management, localized treatment, and systemic drug delivery, making it a leading choice in the transdermal market. It is non-invasive approach, which makes it a preferable alternative for patients who wish to avoid injections or oral medications, especially when long-term or frequent drug administration is required.
Pain management holds the largest share of the industry
The rising focus on pain management among individuals is contributing to the market growth. Transdermal systems provide continuous and controlled release of pain-relieving medications, which is highly beneficial for chronic pain sufferers. This avoids the need for frequent dosing, making it more convenient for patients. Transdermal patches are a non-invasive alternative to oral medications and injections. Transdermal drug delivery systems for pain management provide an opioid-sparing alternative by delivering low and sustained doses that can manage pain effectively while reducing abuse potential.
North America leads the market, accounting for the largest transdermal drug delivery systems market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for transdermal drug delivery systems.
North America has a well-established healthcare system with access to cutting-edge medical technologies. Patients and healthcare providers in the region are more likely to adopt advanced drug delivery systems owing to the availability of infrastructure that supports their use and distribution. North America, particularly the United States, faces high prevalence of chronic diseases, requiring long-term and consistent medication management among individuals. Apart from this, the rising geriatric population in the region is bolstering the market growth. The number of Americans aged 65 and older is predicted to reach 80 million in 2040, as reported by the Urban Institute.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)